Loading...

INO INOVIO PHARMACEUTICALS INC US FDA Inspections 8-K Filing

NV P

N

INOVIO PHARMACEUTICALS INC

(INO)

2023 8-K

Financial Results

Stock Offering Details

Sales Agreement Termination

Financial Results Announcement

Warrant Amendment

FDA BLA Acceptance

Stock Offering Announcement

8-K Filing Summary

Equity Offerings

Financial Statements

Financial Results

Financial Results

Financial Results Announcement

Grant of Performance-Based ...

Financial Results Announcement

Underwriting Agreement for ...

Reverse Stock Split

Stock Split and Amendment A...

Financial Results Announcement

FDA Feedback on Clinical Tr...

Financial Results Announcement

Settlement of Stockholder D...

Compensation Committee adop...

Earnings Reports

Financial Results Announcement

Costs Associated with Exit ...

External Links:

INOVIO Pharmaceuticals has received feedback from the FDA that data from its Phase 1/2 clinical trial can be used to support the submission of a Biologic License Application (BLA) for its lead product candidate INO-3107.

AI Assistant

INOVIO PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.